Literature DB >> 15047556

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.

Chris Stone1, Mounir Ait-Khaled, Charles Craig, Philip Griffin, Margaret Tisdale.   

Abstract

Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (with reduced susceptibility to all three inhibitors) and then Y115F. TFV-containing regimens might increase K65R selection, which confers multiple nucleoside reverse transcriptase inhibitor resistance.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15047556      PMCID： PMC375323          DOI： 10.1128/AAC.48.4.1413-1415.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.

Authors:  M Tisdale; T Alnadaf; D Cousens
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.

Authors:  C A Boucher; W Keulen; T van Bommel; M Nijhuis; D de Jong; M D de Jong; P Schipper; N K Back
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.

Authors:  B L Robbins; R V Srinivas; C Kim; N Bischofberger; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Authors:  Nicolas A Margot; Erica Isaacson; Ian McGowan; Andrew K Cheng; Robert T Schooley; Michael D Miller
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

6.  Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

Authors:  M A Wainberg; H Salomon; Z Gu; J S Montaner; T P Cooley; R McCaffrey; J Ruedy; H M Hirst; N Cammack; J Cameron
Journal:  AIDS       Date:  1995-04       Impact factor: 4.177

7.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

Authors:  B A Larder; S D Kemp; P R Harrigan
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

8.  Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

Authors:  D R Kuritzkes; J B Quinn; S L Benoit; D L Shugarts; A Griffin; M Bakhtiari; D Poticha; J J Eron; M A Fallon; M Rubin
Journal:  AIDS       Date:  1996-08       Impact factor: 4.177

9.  Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.

Authors:  M F Kavlick; T Shirasaka; E Kojima; J M Pluda; F Hui; R Yarchoan; H Mitsuya
Journal:  Antiviral Res       Date:  1995-10       Impact factor: 5.970

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  15 in total

Review 1.  Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mark A Wainberg; Bluma G Brenner; Dan Turner
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

2.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

3.  Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.

Authors:  Michael E Abram; Andrea L Ferris; Kalyan Das; Octavio Quinoñes; Wei Shao; Steven Tuske; W Gregory Alvord; Eddy Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

4.  Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.

Authors:  George L Melikian; Soo-Yon Rhee; Jonathan Taylor; W Jeffrey Fessel; David Kaufman; William Towner; Paolo V Troia-Cancio; Andrew Zolopa; Gregory K Robbins; Ron Kagan; Dennis Israelski; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Authors:  Florence Doualla-Bell; Ava Avalos; Bluma Brenner; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Maureen Oliveira; Daniella Moisi; Ndwapi Ndwapi; Howard Moffat; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

6.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Authors:  N A Margot; J M Waters; M D Miller
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

8.  Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

Authors:  Anna Schneider; Angela Corona; Imke Spöring; Mareike Jordan; Bernd Buchholz; Elias Maccioni; Roberto Di Santo; Jochen Bodem; Enzo Tramontano; Birgitta M Wöhrl
Journal:  Nucleic Acids Res       Date:  2016-02-04       Impact factor: 16.971

9.  Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.

Authors:  Vasudevan Achuthan; Kamlendra Singh; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2016-12-27       Impact factor: 3.162

Review 10.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.